Oliver Fetzer

Oliver Fetzer is CEO and a board member of Synthetic Genomics, since 2014. Previously, he was president and CEO of Cerulean Pharma, which develops nanoparticle drug conjugate oncology therapeutics. Prior to that, Fetzer served for five years in positions of increasing responsibility at Cubist Pharmaceuticals, including senior vice president of corporate development and chief business officer. He began his career at Boston Consulting Group, first as a consultant and ultimately became partner and managing director. Fetzer has served on the board of Tecan Group AG since 2011 and the Arena Pharmaceuticals board since 2017. He previously served on the boards of Auxilium Pharmaceuticals and Cerulean Pharma.